Last reviewed · How we verify
PfSPZ-LARC2 Vaccine
PfSPZ-LARC2 Vaccine is a Biologic drug developed by Sanaria Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | PfSPZ-LARC2 Vaccine |
|---|---|
| Sponsor | Sanaria Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults (PHASE1)
- Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso (PHASE1)
- Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PfSPZ-LARC2 Vaccine CI brief — competitive landscape report
- PfSPZ-LARC2 Vaccine updates RSS · CI watch RSS
- Sanaria Inc. portfolio CI
Frequently asked questions about PfSPZ-LARC2 Vaccine
What is PfSPZ-LARC2 Vaccine?
PfSPZ-LARC2 Vaccine is a Biologic drug developed by Sanaria Inc..
Who makes PfSPZ-LARC2 Vaccine?
PfSPZ-LARC2 Vaccine is developed by Sanaria Inc. (see full Sanaria Inc. pipeline at /company/sanaria-inc).
What development phase is PfSPZ-LARC2 Vaccine in?
PfSPZ-LARC2 Vaccine is in Phase 1.
Related
- Manufacturer: Sanaria Inc. — full pipeline
- Compare: PfSPZ-LARC2 Vaccine vs similar drugs
- Pricing: PfSPZ-LARC2 Vaccine cost, discount & access